Catyalyst Pharma (NASDAQ: CPRX) announced the initiation of a project to develop a generic equivalent of Sabril (vigabatrin). Sabril® is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE